SumanKambhampatiMD

PubMed

• A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
  Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri, Yogen Saunthararajah, Kira Gritsman
  Blood. 2024-11-28
• Dofetilide unmasks long QT in a patient presenting with atrial fibrillation-induced cardiomyopathy.
  Nikhila Chelikam, Suman Kambhampati, Aashish Katapadi, Dhanunjaya Lakkireddy
  Heartrhythm Case Reports. 2024-10-01
• 1 citations
  -class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
  Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter
  Future Oncology. 2024-01-01

Abstracts/Posters

• Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inpatient HospitalizationÍs Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018